drugset / Trial / NCT02044367

Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers

NCT02044367

Phase 1 Completed 54 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

To investigate the relative bioavailability of dabigatran etexilate as pellets on food and of dabigatran etexilate as granules resolved in reconstitution solution, each with dabigatran etexilate as capsule following oral administration. To evaluate acceptability and palatability of Pellets sprinkled on food and Oral Liquid Formulation

Timeline

Start
2014-01
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 150 mg Oral

Indications

No indication recorded.